feedburner

Enter your email address:

Delivered by FeedBurner

The COVID-19 Vaccine Rollout: What’s Ahead?

Event Date as Display String:

Friday, January 22, 2021, 12:00pm - 1:00pm

URL:

https://hsph.me/vaccinerollout

Event Description:

Gazette Classification: Science,Special Events Organization/Sponsor:
The Forum at Harvard T.H. Chan School of Public Health Speaker(s):
Moderator:&nbsp;<strong>Scott Hensley</strong><br /><em>Editor, NPR
Science</em><br /><br /><strong>Barry R. Bloom</strong><br /><em>Joan
and Jack Jacobson Research Professor of Public Health, and Former
Dean, Harvard T.H. Chan School of Public Health</em><br /><br
/><strong>Marc Lipsitch</strong><br /><em>Professor of Epidemiology,
Harvard T.H. Chan School of Public Health</em><br /><br
/><strong>Nancy Messonnier</strong><br /><em>Director of the National
Center for Immunization and Respiratory Diseases, Centers for Disease
Control and Prevention</em><br /><br /><strong>Sandra
Nelson</strong><br /><em>Associate Physician, Division of Infectious
Diseases, Massachusetts General Hospital</em> Cost: Free webcast
Ticket Web Link: https://hsph.me/vaccinerollout Contact Info:
theforum@hsph.harvard.edu Harvard Key Required: No Link:
https://hsph.me/vaccinerollout As the rollout of COVID-19 vaccines
unfolds in the United States, numerous questions around distribution,
supply, hesitancy and efficacy persist. And the stakes have never been
higher, as numbers of deaths and cases repeatedly break records. In
this discussion, experts will review the COVID-19 vaccine distribution
plan, address safety concerns, explore upcoming expected vaccines, and
discuss implications of virus variants.

UID:

http://uid.trumba.com/event/150427727

Event Start Date as Date Type:

Friday, January 22, 2021 - 12:00 to 13:00

Thumbnail:

https://www.trumba.com/i/DgBcVLmIFEDE5WdFPKYC2LAD.jpg

Detail Image:

https://www.trumba.com/i/DgC%2ATgTjuK8xy6RO5DJ8GYWc.jpg

Feature Image:

Featured:

No

https://www.harvard.edu/preview/featured/events/covid-19-vaccine-rollout-what-s-ahead



0 comments:

Post a Comment